Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Molecular Partners AG - American Depositary Shares
(NQ:
MOLN
)
4.520
+0.005 (+0.11%)
Streaming Delayed Price
Updated: 2:06 PM EST, Dec 5, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Molecular Partners AG - American Depositary Shares
< Previous
1
2
3
4
Next >
Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action
November 12, 2025
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting
November 03, 2025
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025
November 03, 2025
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025
October 30, 2025
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025
August 25, 2025
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics
August 21, 2025
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025
June 22, 2025
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025
June 11, 2025
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway
June 10, 2025
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners to Present at Upcoming Investor Conferences
May 19, 2025
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Reports Financial Results and Highlights from Q1 2025
May 15, 2025
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025
April 25, 2025
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Announces all Board Proposals Approved at Annual General Meeting
April 16, 2025
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners to hold three poster presentations at AACR 2025
March 25, 2025
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Publishes Invitation to Annual General Meeting 2025
March 25, 2025
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024
March 06, 2025
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call
February 28, 2025
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer
January 12, 2025
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference
January 12, 2025
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January
December 17, 2024
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024
December 08, 2024
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024
November 07, 2024
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition
November 05, 2024
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going
October 31, 2024
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Announces Pricing of $20 Million Underwritten Offering
October 25, 2024
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024
October 22, 2024
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics
October 22, 2024
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting
October 04, 2024
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024
September 27, 2024
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Reports H1 2024 Corporate Highlights and Financials
August 26, 2024
From
Molecular Partners
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
